A Phase 4 interventional study of Rosuvastatin(Cresnon®) and Rosuvastatin(Crestor®) in Hyperlipidemia, sponsored by Dong-A ST Co., Ltd.. Completed at 1 site in Korea, Republic of. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2015-07-07.
Sponsored by Dong-A ST Co., Ltd. · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies testing rosuvastatin in Hyperlipidemias — 1 open to participants now, 2 under way, 1 of them phase 3. rosuvastatin · Hyperlipidemias.
Among the 30 studies testing rosuvastatin in Hyperlipidemias, this one is the 11th largest by enrollment, is one of 4 that started in 2014, is one of 10 in phase 4, and was the 16th registered.
862 studies on the registry are indexed under Hyperlipidemias; 109 are open to participants now.
Browse Hyperlipidemias studies →1 of the 30 studies testing rosuvastatin in Hyperlipidemias is open now, in 1 country. Recruiting first, the newest first:
Prof. Maurovich-Horvat Pál · Sites in Hungary
Ages 45–75
By country, each count listing its studies:
rosuvastatin: first FDA approval 2003 (CRESTOR). What it is approved for, and how studies give it, is on its page →
Of the 67 Hyperlipidemias studies recruiting now, 27 (40%) set no upper age limit and 32 (48%) stop at 75 or younger; 8 take children under 18; 16 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 5 · Phase 3 8 · Phase 4 10
First in 2004; this study’s year is marked. 4 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 223 is above the median of 88 across 735 interventional studies indexed under Hyperlipidemias.
Median enrollment 114 across the 30 interventional studies. Of the 21 that completed or were terminated, 8 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 30 have an industry lead sponsor. The 10 most frequent:
Dong-A ST Co., Ltd. is the lead sponsor of 122 studies on the registry; 9 are open to participants now.
Dong-A ST Co., Ltd. has 1 study filed under Hyperlipidemias — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 30 studies testing rosuvastatin in Hyperlipidemias, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Comparison of the efficacy and safety of Cresnon® and Crestor® in patients with hyperlipidemia
Inclusion Criteria:
Rosuvastatin 10mg, tablet, q.d.
Drug: Rosuvastatin(Cresnon®)
Rosuvastatin 10mg, tablet, q.d.
Drug: Rosuvastatin(Crestor®)
10mg
10mg
The percent change in LDL-C
Time frame: After taken medication for 8 weeks
The percent change in total cholesterol, Triglyceride, HDL-C, non-HDL-C, and non-HDL-C/HDL-C
Time frame: After taken medication for 8 weeks
The proportion of subjects reaching LDL-C targeted level in accordance with the treatment guidelines for dyslipidemia released by Korean Society of Lipidology and Atherosclerosis
Time frame: After taken medication for 8 weeks
The record gives a start of Sep 2014 and a primary completion of Jun 2015. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rosuvastatin